Category Archives: Pharming

Prodarsan® Granted Orphan Drug Designation From FDA

Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today that its wholly owned subsidiary DNage BV (“DNage”) has received a notice from the US Food and Drug Administration (“FDA”) that its product Prodarsan® has been awarded an Orphan Drug designation for the treatment of Cockayne Syndrome. Prodarsan® is a combination of two small… Read More »